Aterosclerose: Acesso Aberto

Abstrato

Short Review: Progress of Lipid-Lowering Therapies & Where are we Heading?

Willemien van Zwol, Peter J Lansberg, Jan Albert Kuivenhoven

Times are exciting when it comes to numerous new treatment options for dyslipidaemia. Here, we provide a short update on the developments over the last year. While expectations are high, and affordability of new therapies are a concern, their ultimate application still largely depends proof of reduced morbidity and mortality from atherosclerotic cardiovascular disease.